Veröffentlichungen

  • Combining open and laparoscopic surgery for partial nephrectomy. Pahernik S, Reiter M, Hatiboglu G, Huber J, Pfitzenmaier J, Haferkamp A, Hohenfellner M. J Endourol. 2011 May; 25(5):821-4. Epub 2011 Apr 19.

  • Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapy. Ihrig A, Keller M, Hartmann M, Debus J, Pfitzenmaier J, Hadaschik B, Hohenfellner M, Herzog W, Huber J. BJU Int. 2011 Mar 16. doi: 10.1111/j.1464-410X.2011.10082.x.

  • Prognostic variables for shockwave lithotripsy (SWL) treatment success: no impact of body mass index (BMI) using a third generation lithotripter. Hatiboglu G, Popeneciu V, Kurosch M, Huber J, Pahernik S, Pfitzenmaier J, Haferkamp A, Hohenfellner M. BJU Int. 2011 Feb 22. doi: 10.1111/j.1464-410X.2010.10007.x.

  • PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy. Hofner T, Pfitzenmaier J, Alrabadi A, Pahernik S, Hadaschik B, Wagener N, Djakovic N, Haferkamp A, Hohenfellner M. World J Urol. 2010 Dec 31.

  • Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M. BMC Cancer. 2010 Oct 4;10:524.

  • Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Breuninger S, Reidenbach S, Sauer CG, Ströbel P, Pfitzenmaier J, Trojan L, Hofmann I. Am J Pathol. 2010 May;176(5):2509-19. Epub 2010 Mar 26.

  • Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications. Haferkamp A, Kurosch M, Pritsch M, Hatiboglu G, Macher-Goeppinger S, Pfitzenmaier J, Pahernik S, Wagener N, Hohenfellner M. Ann Surg Oncol. 2010 Feb;17(2):544-51. Epub 2009 Dec 1.

  • Editorial comment. Pfitzenmaier J. J Urol. 2009 Oct;182(4):1363. Epub 2009 Aug 14. No abstract available

  • Functional results 1 year after laser vaporization of the prostate: the impact of age. Buse S, Pfitzenmaier J, Wagener N, Haferkamp A, Hohenfellner M. J Endourol. 2009 Aug;23(8):1339-42.

  • Hormonal therapy in the elderly prostate cancer patient. Pfitzenmaier J, Altwein JE. Dtsch Arztebl Int. 2009 Apr;106(14):242-7. Epub 2009 Apr 3. Review.

  • [Immunomodulatory treatment approaches for prostate cancer]. Reiter MA, Pfitzenmaier J, Hohenfellner M, Haferkamp A. Urologe A. 2009 Jul;48(7):755-63. Review. German.

  • Survival in prostate cancer patients > or = 70 years after radical prostatectomy and comparison to younger patients. Pfitzenmaier J, Pahernik S, Buse S, Haferkamp A, Djakovic N, Hohenfellner M. World J Urol. 2009 Oct;27(5):637-42. Epub 2009 Apr 26.

  • [Kidney injuries]. Pfitzenmaier J, Buse S, Haferkamp A, Pahernik S, Djakovic N, Hohenfellner M. Unfallchirurg. 2009 Mar;112(3):317-25; quiz 326. Review. German.

  • [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis]. Pfitzenmaier J, Altwein JE. Aktuelle Urol. 2009 Mar;40(2):100-8. Epub 2009 Feb 27. Review. German.

  • Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer. Thomas C, Wiesner C, Melchior SW, Schmidt F, Gillitzer R, Thüroff JW, Pfitzenmaier J. BJU Int. 2009 Jul;104(1):29-34. Epub 2008 Dec 22.

  • Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate. Buse S, Gilfrich C, Hatiboglu G, Huber J, Bedke J, Pfitzenmaier J, Haferkamp A, Hohenfellner M. World J Urol. 2009 Jun;27(3):405-9. Epub 2009 Jan 15.

  • Intestinal reconstruction of the lower urinary tract as a prerequisite for renal transplantation. Djakovic N, Wagener N, Adams J, Gilfrich C, Haferkamp A, Pfitzenmaier J, Toenshoff B, Schmidt J, Hohenfellner M. BJU Int. 2009 Jun;103(11):1555-60. Epub 2008 Dec 8.

  • Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population? Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F, Gilfrich C, Djakovic N, Buse S, Pahernik S, Hohenfellner M. BJU Int. 2009 Apr; 103(7):877-82. Epub 2008 Oct 24.